JP2014510755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510755A5 JP2014510755A5 JP2014502770A JP2014502770A JP2014510755A5 JP 2014510755 A5 JP2014510755 A5 JP 2014510755A5 JP 2014502770 A JP2014502770 A JP 2014502770A JP 2014502770 A JP2014502770 A JP 2014502770A JP 2014510755 A5 JP2014510755 A5 JP 2014510755A5
- Authority
- JP
- Japan
- Prior art keywords
- azacytidine
- salt
- protected
- acid
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470392P | 2011-03-31 | 2011-03-31 | |
| US61/470,392 | 2011-03-31 | ||
| PCT/US2012/031059 WO2012135405A1 (en) | 2011-03-31 | 2012-03-29 | Systhesis of 5-azacytidine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510755A JP2014510755A (ja) | 2014-05-01 |
| JP2014510755A5 true JP2014510755A5 (https=) | 2015-05-07 |
| JP6289361B2 JP6289361B2 (ja) | 2018-03-07 |
Family
ID=46000343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502770A Active JP6289361B2 (ja) | 2011-03-31 | 2012-03-29 | ５−アザシチジンの合成 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9951098B2 (https=) |
| EP (1) | EP2691408B1 (https=) |
| JP (1) | JP6289361B2 (https=) |
| KR (1) | KR20140019820A (https=) |
| CN (1) | CN103619864A (https=) |
| AU (1) | AU2012236476A1 (https=) |
| BR (1) | BR112013025167A2 (https=) |
| IL (1) | IL228604A0 (https=) |
| MX (1) | MX2013010945A (https=) |
| RU (1) | RU2013148580A (https=) |
| SG (1) | SG193622A1 (https=) |
| WO (1) | WO2012135405A1 (https=) |
| ZA (1) | ZA201307142B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3692983T3 (pl) | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
| JP2014503597A (ja) | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | シチジンアナログの医薬組成物及びその使用方法 |
| WO2014160698A1 (en) * | 2013-03-26 | 2014-10-02 | Celgene Corporation | SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| US10221216B2 (en) | 2013-04-11 | 2019-03-05 | Carnegie Mellon University | Template-directed γPNA synthesis process and γPNA targeting compounds |
| WO2014169206A2 (en) | 2013-04-11 | 2014-10-16 | Carnegie Mellon University | Divalent nucleobase compounds and uses therefor |
| CN103450303A (zh) * | 2013-09-04 | 2013-12-18 | 重庆泰濠制药有限公司 | 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法 |
| CN104672289A (zh) * | 2013-11-29 | 2015-06-03 | 南京圣和药业股份有限公司 | 一种阿扎胞苷杂质的制备方法 |
| WO2017183215A1 (ja) * | 2016-04-21 | 2017-10-26 | 大原薬品工業株式会社 | ５－アザシチジン類の糖部シリルエーテル誘導体 |
| JP7573965B2 (ja) * | 2016-09-26 | 2024-10-28 | カーネギー メロン ユニバーシティ | 二価核酸塩基化合物およびそれらの使用 |
| CN109305992A (zh) * | 2017-07-28 | 2019-02-05 | 江苏先声药业有限公司 | 一种阿扎胞苷的制备方法 |
| CN109988207B (zh) * | 2017-12-29 | 2022-01-04 | 江苏豪森药业集团有限公司 | 阿扎胞苷晶型的制备方法 |
| CN110092807A (zh) * | 2018-01-30 | 2019-08-06 | 中国医学科学院药物研究所 | 一种高纯、低灼烧残渣的制备阿扎胞苷的方法 |
| EP3749298B1 (en) | 2018-02-07 | 2023-04-05 | Lovelace Biomedical Research Institute | Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer |
| KR20190136284A (ko) * | 2018-05-30 | 2019-12-10 | 주식회사 삼양바이오팜 | 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 |
| WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
| JP2023524522A (ja) | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤 |
| CN113201039B (zh) * | 2021-05-19 | 2022-04-29 | 南京德克瑞医药化工有限公司 | 一种医药中间体2’,3’,5’-三乙酰阿扎胞苷的制备方法 |
| US20250195653A1 (en) | 2023-11-28 | 2025-06-19 | Sanofi | Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1050899A (https=) | 1963-12-22 | |||
| CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| CH507969A (de) | 1968-11-12 | 1971-05-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| DE2012888C3 (de) | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
| FR2123632A6 (en) | 1971-01-26 | 1972-09-15 | Ceskoslovenska Akademie Ved | Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine |
| DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
| DE2508312A1 (de) | 1975-02-24 | 1976-09-02 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| DE2757365A1 (de) | 1977-12-20 | 1979-06-21 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| ATE238328T1 (de) | 1996-10-16 | 2003-05-15 | Ribapharm Inc | Monozyklische l-nukleoside, analoga und ihre anwendungen |
| CA2499036A1 (en) | 2002-09-24 | 2004-04-08 | Koronis Pharmaceuticals, Incorporated | 1,3,5-triazines for treatment of viral diseases |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| CN102349927A (zh) | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| US20060063735A1 (en) * | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20080057086A1 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| WO2008088779A2 (en) * | 2007-01-11 | 2008-07-24 | Ivax Pharmaceuticals S.R.O. | Solid state forms of 5-azacytidine and processes for preparation thereof |
| US20110288042A1 (en) | 2007-08-02 | 2011-11-24 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
| EP2048151A1 (en) | 2007-10-10 | 2009-04-15 | Cilag AG | Method for producing nucleosides by direct glycosylation of the nucleoside base |
| EP2211870A1 (en) | 2007-11-01 | 2010-08-04 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| PL3692983T3 (pl) | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
| WO2010014883A2 (en) | 2008-08-01 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
| EP2520581A1 (en) | 2008-08-06 | 2012-11-07 | Sicor, Inc. | Method for the determination the purity of 5-Azacytidine |
| JP5650643B2 (ja) * | 2008-08-08 | 2015-01-07 | サイノファーム タイワン リミテッド | ５−アザシトシンヌクレオシド及びその誘導体の製造方法 |
| US20110042247A1 (en) | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
| IT1399195B1 (it) | 2010-03-30 | 2013-04-11 | Chemi Spa | Processo per la sintesi di azacitidina e decitabina |
-
2012
- 2012-03-29 CN CN201280026401.3A patent/CN103619864A/zh active Pending
- 2012-03-29 RU RU2013148580/04A patent/RU2013148580A/ru not_active Application Discontinuation
- 2012-03-29 SG SG2013071915A patent/SG193622A1/en unknown
- 2012-03-29 WO PCT/US2012/031059 patent/WO2012135405A1/en not_active Ceased
- 2012-03-29 EP EP12716820.1A patent/EP2691408B1/en active Active
- 2012-03-29 AU AU2012236476A patent/AU2012236476A1/en not_active Abandoned
- 2012-03-29 JP JP2014502770A patent/JP6289361B2/ja active Active
- 2012-03-29 US US14/007,955 patent/US9951098B2/en active Active
- 2012-03-29 BR BR112013025167A patent/BR112013025167A2/pt not_active IP Right Cessation
- 2012-03-29 KR KR1020137028446A patent/KR20140019820A/ko not_active Withdrawn
- 2012-03-29 MX MX2013010945A patent/MX2013010945A/es not_active Application Discontinuation
-
2013
- 2013-09-23 ZA ZA2013/07142A patent/ZA201307142B/en unknown
- 2013-09-29 IL IL228604A patent/IL228604A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510755A5 (https=) | ||
| RU2013148580A (ru) | Синтез 5-азацитидина | |
| CN106061972B (zh) | 5-氟-4-亚氨基-3-(烷基/取代烷基)-1-(芳基磺酰基)-3,4-二氢嘧啶-2(1h)-酮及其制备方法 | |
| TWI657088B (zh) | 製造稠合雜環化合物之方法 | |
| TWI663160B (zh) | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 | |
| TWI658042B (zh) | 雜環化合物的合成 | |
| JP2014521726A5 (https=) | ||
| JP2013505259A5 (https=) | ||
| JP2010503694A5 (https=) | ||
| JP2010505926A5 (https=) | ||
| JP2013535220A5 (https=) | ||
| JP2018502909A5 (https=) | ||
| RU2014126224A (ru) | Способ получения и очистки солей акриламидо-2-метилпропансульфоновой кислоты | |
| JP7144873B2 (ja) | スガマデクスナトリウム塩の製造方法 | |
| US9624258B2 (en) | Polymorph of regadenoson | |
| WO2017221214A1 (en) | Crystalline forms of salts of lenvatinib | |
| TWI545114B (zh) | 製備聯苯基咪唑化合物之方法 | |
| JP2010512392A5 (https=) | ||
| JP2014520796A5 (https=) | ||
| CN108623602A (zh) | 一种制备和纯化依鲁替尼的方法 | |
| JP2017514846A5 (https=) | ||
| KR102702677B1 (ko) | 피마살탄 및 그의 제조 중간체의 제조방법 | |
| CN108017573A (zh) | 4-亚甲基哌啶或其酸加成盐的制备方法 | |
| KR100839322B1 (ko) | Ｂ형 간염 치료제 클레부딘의 개선된 제조방법 | |
| TWI364282B (en) | Cefcapene pivoxil methanesulfonic acid salt |